Uridine monophosphate,
does it really help with Memory, cognition, and synaptic health?
research showsA genuine double-blind RCT gave UMP-Na2 alone for 12 weeks to 99 healthy middle-aged and older Japanese adults and found a positive memory endpoint at 600 mg. However, it was a manufacturer-linked study with Yamasa authors, conducted by Ortho Medico, and remains a single paper in a Japanese commercial journal; rule ②-b caps the grade at C. Synaptic health rests only on an MRS surrogate in 17 participants.
ads claimMarketed UMP products use terms such as 'memory,' 'brain phospholipids,' 'synapse formation,' and 'dopamine receptor support.' Direct human evidence consists of one 12-week memory-test trial of a specific 300 or 600 mg product, while synaptic-structure claims mainly come from animal data and human surrogate markers.
Useful facts when choosing a product
- The UMP-only RCT used 300 or 600 mg/day, and the 600 mg group had a positive primary composite-memory endpoint.
- The trial was conducted by authors from the UMP manufacturer Yamasa and a contract clinical organization.
- Souvenaid/Fortasyn is a multinutrient containing DHA, EPA, choline, phospholipids, vitamins, and selenium in addition to UMP.
- No safety problem was reported in the 12-week trial, but long-term UMP-only supplement data are limited.
What the research actually shows
Nakagawara 2022 assigned 99 Japanese adults aged 40 or older who perceived memory decline but did not have dementia to UMP 300 mg, 600 mg, or placebo. After 12 weeks, the 600 mg group improved on the primary Cognitrax composite-memory endpoint, while visual and verbal memory showed improvement trends; however, two authors were employees of the UMP manufacturer Yamasa, and this is a single study. Agarwal 2010 gave 17 healthy men uridine, not UMP, at 2 g/day for seven days and found increased brain phosphomonoesters and phosphoethanolamine by MRS, but it was not a cognitive-efficacy trial. An acute combination trial of DHA, choline, and UMP found no cognitive difference, while Souvenaid/Fortasyn studies also contain many nutrients in addition to UMP and cannot isolate its effect.
Why this is classified as C (42)
The genuine 99-person UMP-Na2-only RCT supports C for memory through its positive 600 mg endpoint. However, the Yamasa and Ortho Medico manufacturer linkage, a single Japanese commercial-journal paper, unconfirmed PMID and DOI, and no independent replication cap it at C under rule ②-b; synaptic health is D because only a 17-person MRS surrogate is available. The overall result is C with 42 points.
Counterpoint. The 12-week composite-memory signal at 600 mg/day is a concrete result for an independent follow-up trial. This assessment does not broaden it to cognition overall or synaptic health.
Rejudgment record. Reassessment (cross-check reflected) — A 12-week UMP-Na2-only RCT in 99 healthy middle-aged and older adults found a positive 600 mg memory endpoint, but it is a single manufacturer-linked paper with Yamasa authors, conducted by Ortho Medico and published in a Japanese commercial journal, so rule ②-b caps the grade at C; synaptic health has only a 17-person MRS surrogate
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Memory | C | A 99-person UMP-Na2-only RCT found a positive 600 mg memory endpoint, but it was manufacturer-linked and lacks independent replication |
| Synaptic health | D | Only a 17-person MRS surrogate is available |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Nakagawara K et al. 2022 | Randomized double-blind placebo-controlled parallel trial | 99 | Authors employed by manufacturer Yamasa; conducted by Ortho Medico | Primary Cognitrax composite-memory endpoint and other cognitive domains | UMP 600 mg/day for 12 weeks improved composite memory; 300 mg was not positive on the primary endpoint in the overall population. | Key, manufacturer-linked |
| Agarwal N et al. 2010 | Randomized placebo-controlled MRS study | 17 | U.S. public research support | Brain phosphomonoesters and phosphoethanolamine | Uridine 2 g/day for seven days increased selected phospholipid precursors, but cognitive or synaptic clinical efficacy was not measured. | Surrogate |
| Bunn JA et al. 2018 | Randomized double-blind crossover trial | 20 | Unknown | ImPACT cognition and exercise performance | A single combination dose of UMP 250 mg, DHA 1500 mg, and alpha-GPC 500 mg did not differ from placebo on cognition. | Supportive, combination |
| Scheltens P et al. 2010 | Randomized double-blind controlled trial | 225 | Supported by Danone Research with employee authors | Delayed verbal recall and ADAS-cog | A UMP-containing multinutrient improved delayed recall, but ADAS-cog and other clinical measures were unchanged. | Combination extrapolation |
Receipt — 5 References
All 5 cited sources were verified for existence at the original page (as of 2026-07-13).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-13 · Corrections: none
Cite this verdict
[Chamgap] Uridine monophosphate (UMP) x memory, cognition, and synaptic health — Evidence Grade C·42. 5 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/cognition/uridine-monophosphate-memory-cognition-synapse/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.